SI0710230T1 - 1,5-benzodiazepine derivatives useful as cck or gastrin antagonists - Google Patents

1,5-benzodiazepine derivatives useful as cck or gastrin antagonists

Info

Publication number
SI0710230T1
SI0710230T1 SI9430207T SI9430207T SI0710230T1 SI 0710230 T1 SI0710230 T1 SI 0710230T1 SI 9430207 T SI9430207 T SI 9430207T SI 9430207 T SI9430207 T SI 9430207T SI 0710230 T1 SI0710230 T1 SI 0710230T1
Authority
SI
Slovenia
Prior art keywords
cck
derivatives useful
benzodiazepine derivatives
gastrin antagonists
gastrin
Prior art date
Application number
SI9430207T
Other languages
English (en)
Slovenian (sl)
Inventor
Daniele Donati
Antonella Ursini
Mauro Corsi
Original Assignee
Glaxo Wellcome S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome S.P.A. filed Critical Glaxo Wellcome S.P.A.
Publication of SI0710230T1 publication Critical patent/SI0710230T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SI9430207T 1993-07-20 1994-07-18 1,5-benzodiazepine derivatives useful as cck or gastrin antagonists SI0710230T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939314981A GB9314981D0 (en) 1993-07-20 1993-07-20 Chemical compounds
PCT/EP1994/002353 WO1995003285A1 (en) 1993-07-20 1994-07-18 1,5-benzodiazepine derivatives useful as cck or gastrin antagonists
EP94924257A EP0710230B1 (en) 1993-07-20 1994-07-18 1,5-benzodiazepine derivatives useful as cck or gastrin antagonists

Publications (1)

Publication Number Publication Date
SI0710230T1 true SI0710230T1 (en) 1999-02-28

Family

ID=10739096

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9430207T SI0710230T1 (en) 1993-07-20 1994-07-18 1,5-benzodiazepine derivatives useful as cck or gastrin antagonists

Country Status (32)

Country Link
US (1) US5716953A (ko)
EP (1) EP0710230B1 (ko)
JP (1) JP3587849B2 (ko)
KR (1) KR100347287B1 (ko)
CN (1) CN1050835C (ko)
AP (1) AP492A (ko)
AT (1) ATE171167T1 (ko)
AU (1) AU687858B2 (ko)
CA (1) CA2167308A1 (ko)
CO (1) CO4290299A1 (ko)
CZ (1) CZ290472B6 (ko)
DE (1) DE69413405T2 (ko)
DK (1) DK0710230T3 (ko)
EC (1) ECSP941120A (ko)
ES (1) ES2123812T3 (ko)
FI (1) FI960223A (ko)
GB (1) GB9314981D0 (ko)
HR (1) HRP940411B1 (ko)
HU (1) HU222439B1 (ko)
IL (1) IL110366A (ko)
IS (1) IS4190A (ko)
MY (1) MY118638A (ko)
NO (1) NO313288B1 (ko)
NZ (1) NZ271075A (ko)
PE (1) PE8295A1 (ko)
PL (1) PL175609B1 (ko)
RU (1) RU2135485C1 (ko)
SI (1) SI0710230T1 (ko)
SV (1) SV1994000031A (ko)
TW (1) TW290542B (ko)
WO (1) WO1995003285A1 (ko)
ZA (1) ZA945238B (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739129A (en) * 1994-04-14 1998-04-14 Glaxo Wellcome Inc. CCK or gastrin modulating 5-heterocyclic-1, 5 benzodiazepines
PE27497A1 (es) * 1994-04-15 1997-08-07 Glaxo Inc Derivados de 1,5 benzodiazepina
WO1998002419A1 (fr) * 1996-07-12 1998-01-22 Chugai Seiyaku Kabushiki Kaisha Inhibiteurs de proliferation de cellules cancereuses
US6683075B1 (en) 1996-12-23 2004-01-27 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US6958330B1 (en) 1998-06-22 2005-10-25 Elan Pharmaceuticals, Inc. Polycyclic α-amino-ε-caprolactams and related compounds
US6569851B1 (en) 1998-06-22 2003-05-27 Elan Pharmaceutials, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
TR200201026T2 (tr) 1999-10-15 2002-08-21 F.Hoffmann-La Roche Ag Benzodiazepin türevleri
US20050192265A1 (en) * 2003-03-20 2005-09-01 Thompson Richard C. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
CA2813136A1 (en) * 2004-02-27 2005-09-15 Aortx, Inc. Prosthetic heart valve delivery systems and methods
EP2137167B1 (en) * 2007-04-19 2011-08-10 F. Hoffmann-La Roche AG Dihydro-benzo[b][1,4]diazepin-2-one sulfonamide derivatives
RU2540464C2 (ru) * 2012-05-28 2015-02-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Водорастворимое производное амида салициловой кислоты, обладающее транквилизирующей, ноотропной и анальгезирующей активностью
CN103435562B (zh) * 2013-08-26 2016-02-24 华东理工大学 6-取代苯并二氮卓-2,4-二酮类化合物及其用途
RU2702359C1 (ru) * 2019-06-04 2019-10-08 Федеральное государственное бюджетное научное учреждение Уфимский федеральный исследовательский центр Российской академии наук Способ получения 2,2,4-триалкил-2,3-дигидро-1Н-1,5-бензодиазепинов

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2641280B1 (fr) * 1988-12-29 1994-01-21 Roussel Uclaf Nouveaux derives de la 2,4-dioxo 2,3,4,5-tetrahydro 1h-1,5-benzodiazepine, leur procede de preparation et leur application comme medicaments
CA2068355A1 (en) * 1991-05-14 1992-11-15 Mark S. Chambers Benzodiazephine derivatives, compositions containing them and their use in therapy
GEP20001968B (en) * 1992-01-21 2000-03-05 Glaxo Spa Arilthio Compounds as Antibacterial and Antiviral Agents
GB9201181D0 (en) * 1992-01-21 1992-03-11 Glaxo Spa Chemical compounds
GB9225492D0 (en) * 1992-12-05 1993-01-27 Glaxo Group Ltd Amine derivatives

Also Published As

Publication number Publication date
ATE171167T1 (de) 1998-10-15
AP9400657A0 (en) 1994-07-31
HRP940411B1 (en) 2000-12-31
US5716953A (en) 1998-02-10
DE69413405D1 (de) 1998-10-22
JPH09502428A (ja) 1997-03-11
AU7458994A (en) 1995-02-20
FI960223A0 (fi) 1996-01-17
ECSP941120A (es) 1995-01-16
PL175609B1 (pl) 1999-01-29
GB9314981D0 (en) 1993-09-01
NO313288B1 (no) 2002-09-09
HU222439B1 (hu) 2003-07-28
NZ271075A (en) 1998-06-26
DE69413405T2 (de) 1999-04-15
IL110366A (en) 1999-01-26
ES2123812T3 (es) 1999-01-16
AP492A (en) 1996-05-13
CN1138853A (zh) 1996-12-25
ZA945238B (en) 1995-02-09
HU9600124D0 (en) 1996-03-28
TW290542B (ko) 1996-11-11
EP0710230B1 (en) 1998-09-16
IL110366A0 (en) 1994-10-21
RU2135485C1 (ru) 1999-08-27
CA2167308A1 (en) 1995-02-02
KR100347287B1 (ko) 2002-12-06
PL312659A1 (en) 1996-04-29
CO4290299A1 (es) 1996-04-17
PE8295A1 (es) 1995-04-20
MY118638A (en) 2004-12-31
CZ290472B6 (cs) 2002-07-17
AU687858B2 (en) 1998-03-05
DK0710230T3 (da) 1999-06-14
EP0710230A1 (en) 1996-05-08
WO1995003285A1 (en) 1995-02-02
HRP940411A2 (en) 1997-04-30
JP3587849B2 (ja) 2004-11-10
IS4190A (is) 1995-01-21
FI960223A (fi) 1996-03-19
HUT73499A (en) 1996-08-28
CN1050835C (zh) 2000-03-29
CZ17396A3 (en) 1996-07-17
NO960237D0 (no) 1996-01-19
NO960237L (no) 1996-03-19
SV1994000031A (es) 1995-10-04

Similar Documents

Publication Publication Date Title
ZA942571B (en) 1,5 benzodiazepine derivatives
ZA93375B (en) 1,5-benzodiazepine derivatives
IL141908A0 (en) 1,4-benzodiazepine derivatives
AP9701077A0 (en) Substituted 6,5-hetero bicyclic derivatives
AP9701076A0 (en) Substituted 6,6-hetero bicyclic derivatives
GR3030668T3 (en) Condensed indole derivatives as 5ht 4?-receptor antagonists.
AU3461293A (en) Benzodiazepine derivatives, as CCK and gastrin antagonists
HU9600124D0 (en) 1,5-benzodiazepine derivatives useful as cck or gastrin antagonists
AP9500731A0 (en) 1,5 benzodiazepine derivatives
GB2311779B (en) 2,3 benzodiazepine derivatives
HU9502977D0 (en) 1,5-benzodiazepine derivatives having cck and/or gastrin antagonistic activity
AU7228994A (en) 1,5-benzodiazepine derivatives useful as cck or gastrin antagonists
AU6161894A (en) Cholecystokinin antagonists
GR3035910T3 (en) Derivatives of 10,11-dihydro-10-oxo-5h-dibenz/b,f/azepine-5-carboxamide
HU9402902D0 (en) 1,2-dihydro-2-oxo-3-methyl-sulfonyl-aminomethyl-pyridine derivatives
GB9406037D0 (en) 1,5 Benzodiazepine derivatives
ZA953056B (en) 1,5 benzodiazepine derivatives
GB9626308D0 (en) av›3 antagonists
HU9501251D0 (en) 17,20-epoxy-20-substituted-pregnane derivatives
GB9312311D0 (en) New benzodiazepine derivatives

Legal Events

Date Code Title Description
KO00 Lapse of patent

Effective date: 20070227